Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSM8 | ISIN: US87978U1088 | Ticker-Symbol: 3OS
Tradegate
31.03.25
10:46 Uhr
0,722 Euro
+0,005
+0,63 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7050,72210:54
0,7050,72210:48

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrH.C. Wainwright cuts Tempest Therapeutics stock target to $1611
DoTempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans7
DoTempest Therapeutics GAAP EPS of -$1.50 misses by $0.155
DoTempest Therapeutics, Inc. - 10-K, Annual Report2
TEMPEST THERAPEUTICS Aktie jetzt für 0€ handeln
DoTempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update162• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement...
► Artikel lesen
DoTempest Therapeutics, Inc. - 8-K, Current Report3
DiTempest Therapeutics: Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting11
13.03.Tempest Therapeutics: FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)194BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
10.02.Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma243Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif....
► Artikel lesen
07.02.Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)191BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
06.01.Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)318BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
31.12.24Tempest Therapeutics, Inc. - 8-K, Current Report28
06.12.24Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)321BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
06.12.24Tempest Therapeutics, Inc. - 8-K, Current Report3
12.11.24Tempest Therapeutics GAAP EPS of -$0.41 misses by $0.0511
12.11.24Tempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update375Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agreement...
► Artikel lesen
12.11.24Tempest Therapeutics, Inc. - 8-K, Current Report3
12.11.24Tempest Therapeutics schreitet mit Leberkrebs-Medikament zur Phase-3-Studie voran40
12.11.24Tempest Therapeutics advances liver cancer drug to Phase 3 trial9
14.10.24Tempest Therapeutics behält Kursziel und Sektor-Outperform-Rating bei118
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,10